These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 17054068)
1. Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma. Safdar A; Rodriguez MA; Fayad LE; Rodriguez GH; Pro B; Wang M; Romaguera JE; Goy AH; Hagemeister FB; McLaughlin P; Bodey GP; Kwak LW; Raad II; Couch RB J Infect Dis; 2006 Nov; 194(10):1394-7. PubMed ID: 17054068 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months. King JC; Cox MM; Reisinger K; Hedrick J; Graham I; Patriarca P Vaccine; 2009 Nov; 27(47):6589-94. PubMed ID: 19716456 [TBL] [Abstract][Full Text] [Related]
3. Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults. Treanor JJ; Schiff GM; Couch RB; Cate TR; Brady RC; Hay CM; Wolff M; She D; Cox MM J Infect Dis; 2006 May; 193(9):1223-8. PubMed ID: 16586358 [TBL] [Abstract][Full Text] [Related]
4. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming? Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948 [TBL] [Abstract][Full Text] [Related]
5. Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity. Reisinger KS; Block SL; Izu A; Groth N; Holmes SJ J Infect Dis; 2009 Sep; 200(6):849-57. PubMed ID: 19673652 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age. Baxter R; Patriarca PA; Ensor K; Izikson R; Goldenthal KL; Cox MM Vaccine; 2011 Mar; 29(12):2272-8. PubMed ID: 21277410 [TBL] [Abstract][Full Text] [Related]
7. Benefits of increasing the dose of influenza vaccine in residents of long-term care facilities: a randomized placebo-controlled trial. Cools HJ; Gussekloo J; Remmerswaal JE; Remarque EJ; Kroes AC J Med Virol; 2009 May; 81(5):908-14. PubMed ID: 19319953 [TBL] [Abstract][Full Text] [Related]
8. Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age. Vesikari T; Block SL; Guerra F; Lattanzi M; Holmes S; Izu A; Gaitatzis N; Hilbert AK; Groth N Pediatr Infect Dis J; 2012 May; 31(5):494-500. PubMed ID: 22301476 [TBL] [Abstract][Full Text] [Related]
9. [Safety and immunogenicity on three lots of influenza split vaccines among adults]. Zhang ZL; Wang X; Zhu XJ; Zhang Y; Liu Y; Gao ZG; Liang M; Li L; Li JM; Liu RK; Dong XJ; Song GX; Zhang DC; Wang WQ; Han YG; Chen JT Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Jun; 30(6):583-7. PubMed ID: 19957624 [TBL] [Abstract][Full Text] [Related]
10. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant. Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689 [TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and tolerability of inactivated flu vaccine in high risk and healthy children. Avila Aguero ML; Soriano-Fallas A; Umaña-Sauma MA; Ulloa-Gutierrez R; Arnoux S Medicina (B Aires); 2007; 67(4):351-9. PubMed ID: 17891930 [TBL] [Abstract][Full Text] [Related]
12. Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. Madhi SA; Maskew M; Koen A; Kuwanda L; Besselaar TG; Naidoo D; Cohen C; Valette M; Cutland CL; Sanne I Clin Infect Dis; 2011 Jan; 52(1):128-37. PubMed ID: 21148531 [TBL] [Abstract][Full Text] [Related]
13. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102 [TBL] [Abstract][Full Text] [Related]
14. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus. Zuccotti GV; Scaramuzza A; Riboni S; Mameli C; Pariani E; Tanzi E; Zanetti A; Radaelli G Vaccine; 2009 Aug; 27(39):5357-62. PubMed ID: 19607951 [TBL] [Abstract][Full Text] [Related]